Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

Leng S, Bhutani D, Raza S, Assal A, Pan S, Hu J, Wei A, Mapara M, Lentzsch S.

Blood Cancer J. 2020 Feb 3;10(2):13. doi: 10.1038/s41408-020-0278-5. No abstract available.

2.

How I treat a refractory myeloma patient who is not eligible for a clinical trial.

Leng S, Bhutani D, Lentzsch S.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):125-136. doi: 10.1182/hematology.2019000016.

PMID:
31808850
3.

Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?

Premkumar V, Comenzo R, Lentzsch S.

Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):686-688. doi: 10.1016/j.clml.2019.07.003. Epub 2019 Jul 15. No abstract available.

4.

One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.

Edwards CV, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Wall JS, Solomon A, Eisenberger A, Lentzsch S.

Amyloid. 2019;26(sup1):115-116. doi: 10.1080/13506129.2019.1584892. No abstract available.

PMID:
31343323
5.

Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.

Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Pregja S, Osman K, Tsai WY, Landau H, Sanchorawala V.

Amyloid. 2019;26(sup1):113-114. doi: 10.1080/13506129.2019.1583200. No abstract available.

PMID:
31343313
6.

Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.

Bhutani D, Leng S, Lentzsch S.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):555-559. doi: 10.1016/j.clml.2019.03.029. Epub 2019 Apr 1. Review.

PMID:
31262668
7.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, GarcĂ­a-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
8.

Targeting transcription factors in multiple myeloma: evolving therapeutic strategies.

Li S, Vallet S, Sacco A, Roccaro A, Lentzsch S, Podar K.

Expert Opin Investig Drugs. 2019 May;28(5):445-462. doi: 10.1080/13543784.2019.1605354. Epub 2019 Apr 16. Review.

PMID:
30963799
9.

Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.

Leng S, Chen Y, Tsai WY, Bhutani D, Hillyer GC, Lim E, Accordino MK, Wright JD, Hershman DL, Lentzsch S, Neugut AI.

J Natl Compr Canc Netw. 2019 Jan;17(1):22-28. doi: 10.6004/jnccn.2018.7079.

10.

Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance.

Stein EM, Dash A, Bucovsky M, Agarwal S, Fu J, Lentzsch S, Shane E.

Osteoporos Int. 2019 Mar;30(3):629-635. doi: 10.1007/s00198-018-4787-z. Epub 2018 Nov 28.

PMID:
30488275
11.

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, Venner CP, Gasparetto C, Del Col A, Neri P, Reece D, Kauffman M, Shacham S, Unger TJ, Jeha J, Saint-Martin JR, Shah J, Chen C.

Blood. 2018 Dec 13;132(24):2546-2554. doi: 10.1182/blood-2018-06-858852. Epub 2018 Oct 23.

12.

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.

Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, Lentzsch S, Moreau P, Cavo M, Miguel JS, Dimopoulos MA, Rajkumar SV, Durie BGM, Terpos E, Delorme S.

Blood Cancer J. 2018 Oct 4;8(10):95. doi: 10.1038/s41408-018-0124-1.

13.

Beyond NEOD001 for systemic light-chain amyloidosis.

Varga C, Lentzsch S, Comenzo RL.

Blood. 2018 Nov 1;132(18):1992-1993. doi: 10.1182/blood-2018-07-865857. Epub 2018 Sep 21. No abstract available.

PMID:
30242086
14.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

15.

Bone-Modifying Agents: Complicated to Use.

Leng S, Lentzsch S.

J Oncol Pract. 2018 Aug;14(8):469-470. doi: 10.1200/JOP.18.00444. No abstract available.

PMID:
30096274
16.

Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.

Liu A, Li S, Donnenberg V, Fu J, Gollin SM, Ma H, Lu C, Stolz DB, Mapara MY, Monaghan SA, Lentzsch S.

Haematologica. 2018 Oct;103(10):1688-1697. doi: 10.3324/haematol.2018.188227. Epub 2018 Jun 28.

17.

IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation.

Li S, Fu J, Wang H, Ma H, Xu X, Yang YG, Deng S, Mapara MY, Lentzsch S.

Blood Adv. 2018 Mar 13;2(5):492-504. doi: 10.1182/bloodadvances.2017010348.

18.

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.

Leng S, Lentzsch S, Shen Y, Tsai WY, Wright JD, Hershman DL, Neugut AI.

Leuk Lymphoma. 2018 Oct;59(10):2465-2469. doi: 10.1080/10428194.2018.1429605. Epub 2018 Feb 2. No abstract available.

19.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

20.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S.

Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.

Supplemental Content

Loading ...
Support Center